ArticleAmerican journal of cancer research2026
Preoperative nomogram for predicting microvascular invasion and stratifying recurrence risk in early-stage hepatocellular carcinoma.
Article in American journal of cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microvascular invasion (MVI) is a key determinant of early recurrence and poor prognosis in hepatocellular carcinoma (HCC). However, it can only be diagnosed pathologically after surgery, making reliable preoperative prediction challenging. We aimed to establish and validate a practical preoperative model to predict MVI and risk of recurrence in patients with early-stage HCC. A total of 1,196 patients with BCLC 0-A stage HCC who underwent curative liver resection were retrospectively analyzed. Preoperative clinical and radiological variables were evaluated to identify independent predictors of MVI using multivariate logistic regression. A nomogram was constructed and internally validated to estimate the individual probability of MVI, and disease-free survival (DFS) was compared between the risk groups derived from the nomogram. MVI was pathologically confirmed in 327 of the 1,196 patients (27.3%). In the training and validation cohorts, the nomogram incorporating alpha-fetoprotein (AFP), tumor size, neutrophil-to-lymphocyte ratio (NLR), prothrombin time (PT) and age achieved concordance indexes of 0.72 (95% CI, 0.68-0.75) and 0.73 (95% CI, 0.67-0.79), respectively, with good calibration performance. Patients stratified into the high-risk group based on the nomogram-derived score exhibited significantly shorter DFS than those in the low-risk group (P < 0.001), thereby substantiating the model's prognostic utility. Overall, the proposed nomogram model exhibited satisfactory performance in predicting MVI Preoperatively and stratifying recurrence risk in patients with early-stage HCC, thus facilitating individualized risk assessment and treatment planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.